Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society

Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections, became available in China in Dec. 2017. As dose adjustments are based solely on clinical experience of risk toxicity, treatment failure, and emergence of resistance, there is an urgent cli...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Zhejiang University. B. Science 2023-02, Vol.24 (2), p.130-142
Main Authors: Liu, Xiaofen, Huang, Chenrong, Bergen, Phillip J., Li, Jian, Zhang, Jingjing, Chen, Yijian, Chen, Yongchuan, Guo, Beining, Hu, Fupin, Hu, Jinfang, Hu, Linlin, Li, Xin, Qiu, Hongqiang, Shao, Hua, Sun, Tongwen, Wang, Yu, Xu, Ping, Yang, Jing, Yang, Yong, Yu, Zhenwei, Zhang, Bikui, Zhu, Huaijun, Zuo, Xiaocong, Zhang, Yi, Miao, Liyan, Zhang, Jing
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Bacterial diseases
Biomedical and Life Sciences
Biomedicine
Chemotherapy
China
Drug Monitoring - methods
Drug resistance
Gram-negative bacteria
Guideline
Guidelines
Humans
Infections
Monitoring
Optimization
Pharmacology
Polymyxin B
Practice Guidelines as Topic
Telemedicine
Therapeutic drug monitoring
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections, became available in China in Dec. 2017. As dose adjustments are based solely on clinical experience of risk toxicity, treatment failure, and emergence of resistance, there is an urgent clinical need to perform therapeutic drug monitoring (TDM) to optimize the use of polymyxin B. It is thus necessary to standardize operating procedures to ensure the accuracy of TDM and provide evidence for their rational use. We report a consensus on TDM guidelines for polymyxin B, as endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society. The consensus panel was composed of clinicians, pharmacists, and microbiologists from different provinces in China and Australia who made recommendations regarding target concentrations, sample collection, reporting, and explanation of TDM results. The guidelines provide the first-ever consensus on conducting TDM of polymyxin B, and are intended to guide optimal clinical use.
ISSN:1673-1581
1862-1783
DOI:10.1631/jzus.B2200466